SAN MATEO¿ Calif.¿ May 28 /PRNewswire/ -- Results and additional analyses from the Phase II portion of a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented at the Heart Failure Congress, the annual meeting of the Heart Failure Association of the European Society of Cardiology in Nice, France.
Marco Metra, M.D., professor of cardiology at the University of Brescia, Italy, and co-principal investigator of the Pre-RELAX-AHF study, will present the main results from the multicenter, international Pre-RELAX-AHF study at 8:30 a.m. CET on Sunday, May 31, at the Judges' Choice oral abstracts session. Dr. Metra will also present additional analyses of the Pre-RELAX-AHF study during a late-breaking clinical trials session at 11:15 a.m. CET on Monday, June 1. Five posters from the Pre-RELAX-AHF study will also be presented from 8:30 a.m. to 12:30 p.m. CET on Monday, June 1.
Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men and non-pregnant women, including patients with heart failure.
Corthera Inc. is a private biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera's lead product candidate, relaxin, is currently being evaluated in clinical trials for acute heart failure. The company has worldwide rights to develop and commercialize relaxin. For more information, visit www.corthera.com.
Contact: David Schull or Andreas Marathovouniotis Russo Partners 212.845.4271 212.845.4235 email@example.com firstname.lastname@example.org
|SOURCE Corthera Inc.|
Copyright©2009 PR Newswire.
All rights reserved